TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01242423

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: extracorporeal shockwave therapy
Description: ESWT is administered as a one-off treatment on the wound surfaces within 24 hours of a 2nd degree burn trauma and immediately after an intraoperative skin graft excision procedure. A defocused sound head is orthogradely applied to the burn wound or the donor site. 100 impulses/cm² is administered at 20 seconds per cm². The defocused sound head is placed on the wound along with a sterile gel (Lavaseptgel®, Octenidingel®) and a sterile protection foil. The shockwaves deployed are not at an energy density that is painful. This single application of ESWT is followed by routine dressing using Mepitel® in combination with Polyhexanid/Octenidin®.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: extracorporeal shockwave therapy
Description: ESWT is administered as a one-off treatment on the wound surfaces within 24 hours of a 2nd degree burn trauma and immediately after an intraoperative skin graft excision procedure. A defocused sound head is orthogradely applied to the burn wound or the donor site. 100 impulses/cm² is administered at 20 seconds per cm². The defocused sound head is placed on the wound along with a sterile gel (Lavaseptgel®, Octenidingel®) and a sterile protection foil. The shockwaves deployed are not at an energy density that is painful. This single application of ESWT is followed by routine dressing using Mepitel® in combination with Polyhexanid/Octenidin®.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: extracorporeal shockwave therapy
Description: ESWT is administered as a one-off treatment on the wound surfaces within 24 hours of a 2nd degree burn trauma and immediately after an intraoperative skin graft excision procedure. A defocused sound head is orthogradely applied to the burn wound or the donor site. 100 impulses/cm² is administered at 20 seconds per cm². The defocused sound head is placed on the wound along with a sterile gel (Lavaseptgel®, Octenidingel®) and a sterile protection foil. The shockwaves deployed are not at an energy density that is painful. This single application of ESWT is followed by routine dressing using Mepitel® in combination with Polyhexanid/Octenidin®.
Study: NCT03361137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emicizumab
Description: Emicizumab via SC injection at a loading dose 3 mg/kg once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly, or by any other approved maintenance regimen, as long as the participant continues to derive sufficient benefit. Dosing was to be adjusted if the participant had a significant change in body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emicizumab
Description: Emicizumab via SC injection at a loading dose 3 mg/kg once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly, or by any other approved maintenance regimen, as long as the participant continues to derive sufficient benefit. Dosing was to be adjusted if the participant had a significant change in body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emicizumab
Description: Emicizumab via SC injection at a loading dose 3 mg/kg once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly, or by any other approved maintenance regimen, as long as the participant continues to derive sufficient benefit. Dosing was to be adjusted if the participant had a significant change in body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emicizumab
Description: Emicizumab via SC injection at a loading dose 3 mg/kg once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly, or by any other approved maintenance regimen, as long as the participant continues to derive sufficient benefit. Dosing was to be adjusted if the participant had a significant change in body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emicizumab
Description: Emicizumab via SC injection at a loading dose 3 mg/kg once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly, or by any other approved maintenance regimen, as long as the participant continues to derive sufficient benefit. Dosing was to be adjusted if the participant had a significant change in body weight.
Study: NCT01235897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: Different dose levels of MK-2206 will studied, and co-administered with paclitaxel and trastuzumab. MK-2206 will be given orally with a starting dose of 135 mg weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m2 weekly - paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 2 mg/kg weekly after a 1-time loading dose of 4 mg/kg - trastuzumab
Study: NCT05038475

Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-19 antibody test
Description: FDA-approved Immunoassays were used in the study. At the beginning of the study, up to 3 months, ELISA and CLIA immunoassays were adopted to analyze the antibody titers. Thereafter, CLIA was used for longitudinal analysis of antibody titers for consecutive months. Anti

Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-19 antibody test
Description: FDA-approved Immunoassays were used in the study. At the beginning of the study, up to 3 months, ELISA and CLIA immunoassays were adopted to analyze the antibody titers. Thereafter, CLIA was used for longitudinal analysis of antibody titers for consecutive months. Anti
Study: NCT02250222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGD-6972
Description: LGD-6972 sodium salt powder in Captisol ® (betadex \[β-cyclodextrin\] sulfobutylether sodium, NF)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGD-6972
Description: LGD-6972 sodium salt powder in Captisol ® (betadex \[β-cyclodextrin\] sulfobutylether sodium, NF)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGD-6972
Description: LGD-6972 sodium salt powder in Captisol ® (betadex \[β-cyclodextrin\] sulfobutylether sodium, NF)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGD-6972
Description: LGD-6972 sodium salt powder in Captisol ® (betadex \[β-cyclodextrin\] sulfobutylether sodium, NF)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Captisol ®)
Description: betadex \[β-cyclodextrin\] sulfobutylether sodium, NF

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Captisol ®)
Description: betadex \[β-cyclodextrin\] sulfobutylether sodium, NF
Study: NCT02898818

Intervention type: OTHER
Intervention: vaginal and oral swab sample, questionnaire
Description: vaginal and oral swab sample and questionnaire

Intervention type: OTHER
Intervention: vaginal and oral swab sample, questionnaire
Description: vaginal and oral swab sample and questionnaire

Intervention type: OTHER
Intervention: vaginal and oral swab sample, questionnaire
Description: vaginal and oral swab sample and questionnaire

Intervention type: OTHER
Intervention: vaginal and oral swab sample, questionnaire
Description: vaginal and oral swab sample and questionnaire

Intervention type: OTHER
Intervention: vaginal and oral swab sample, questionnaire
Description: vaginal and oral swab sample and questionnaire

Intervention type: OTHER
Intervention: papa smear
Description: Papnicolaou Papa Smear test

Intervention type: OTHER
Intervention: papa smear
Description: Papnicolaou Papa Smear test

Intervention type: OTHER
Intervention: papa smear
Description: Papnicolaou Papa Smear test
Study: NCT02018562

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portex Blueline Ultra Suctionaid Tracheostomy Tube
Study: NCT03497637

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: measurement of FFR
Description: use of pressure-derived FFR to assess the hemodynamic significance of coronary stenoses

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: measurement of Pd/Pa
Description: use of resting distal coronary pressure to aortic pressure ratio (Pd/Pa) to assess the hemodynamic significance of coronary stenoses
Study: NCT04448886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: (iv) fixed dose, administered once per cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: (iv) fixed dose, administered once per cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: (iv) fixed dose, administered twice per cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: (iv) fixed dose, administered twice per cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: (iv) fixed dose, administered twice per cycle
Study: NCT00001711

Intervention type: PROCEDURE
Intervention: MRI
Description: scan of healthy volunteers.
Study: NCT06253832

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conservative surgery for placenta accreta spectrum
Description: The surgical procedure involved a midline incision for the laparotomy approach. Dissection of the uterus from the posterior bladder wall extended down to the cervix, with coagulation of the vesicouterine vessels. Hysterotomy was executed in the upper segment, just above the area of myometrial invasion. Hemostasis of the lower uterus was achieved through either square compression sutures or ligation of the colpouterine vessels. A conservative approach to uterine surgery was considered viable only under conditions of stable hemodynamics and when at least 2 cm of healthy myometrium was visibly intact above the cervix. For cases involving conservative resection, all myometrium affected by invasion and the entire placenta were excised. Subsequently, the uterus was reconstructed using a continuous stitching technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hysterectomy
Description: hysterectomy for placenta accreta spectrum

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hysterectomy
Description: hysterectomy for placenta accreta spectrum
Study: NCT04245111

Intervention type: OTHER
Intervention: Immunofluorescence Imaging
Description: Patients will be administered FDA approved ICG through intravenous injection and imaged by a FDA approved surgical microscope (Pentero or Spy Elite) which is 0.5 meter away from the subject. Both ICG fluorescence and the two imaging systems have been used for routine clinical practice for many years. Figure (a) shows the Schematic sketch of the imaging systems. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA-approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to bone perfusion can be captured by a video rate imaging system.

Intervention type: OTHER
Intervention: Immunofluorescence Imaging
Description: Patients will be administered FDA approved ICG through intravenous injection and imaged by a FDA approved surgical microscope (Pentero or Spy Elite) which is 0.5 meter away from the subject. Both ICG fluorescence and the two imaging systems have been used for routine clinical practice for many years. Figure (a) shows the Schematic sketch of the imaging systems. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA-approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to bone perfusion can be captured by a video rate imaging system.

Intervention type: OTHER
Intervention: Immunofluorescence Imaging
Description: Patients will be administered FDA approved ICG through intravenous injection and imaged by a FDA approved surgical microscope (Pentero or Spy Elite) which is 0.5 meter away from the subject. Both ICG fluorescence and the two imaging systems have been used for routine clinical practice for many years. Figure (a) shows the Schematic sketch of the imaging systems. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA-approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to bone perfusion can be captured by a video rate imaging system.
Study: NCT03587844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: MF/SS Brentuximab vedotin 0.9 mg/kg 0R 1.2 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: LyP Brentuximab vedotin 0.9 mg/kg2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: MF/SS prior brentuximab vedotin-Brentuximab vedotin dose to be determined from Cohort 1
Study: NCT03808974

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational video
Description: Short educational video describing the mid-urethral sling procedure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational leaflet
Description: Standard educational leaflet describing the mid-urethral sling procedure
Study: NCT03299959

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Agili-C implant
Description: Agili-C implant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SSOC
Description: microfracture and/or debridement
Study: NCT03025971

Intervention type: DEVICE
Group type: OTHER
Intervention: J-Valve Transcatheter Aortic valve replacement
Description: Transapical Transcatheter Aortic Valve Replacement
Study: NCT04381832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: Etrumadenant is an A2aR and A2bR antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: Etrumadenant is an A2aR and A2bR antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: Etrumadenant is an A2aR and A2bR antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: Etrumadenant is an A2aR and A2bR antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: Etrumadenant is an A2aR and A2bR antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: Etrumadenant is an A2aR and A2bR antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: Etrumadenant is an A2aR and A2bR antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: Etrumadenant is an A2aR and A2bR antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimberelimab is an anti-PD-1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimberelimab is an anti-PD-1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimberelimab is an anti-PD-1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimberelimab is an anti-PD-1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimberelimab is an anti-PD-1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimberelimab is an anti-PD-1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quemliclustat
Description: Quemliclustat is a Cluster of Differentiation (CD)73 Inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quemliclustat
Description: Quemliclustat is a Cluster of Differentiation (CD)73 Inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide is an androgen receptor inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Enzalutamide is an androgen receptor inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel is type of chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel is type of chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SG
Description: Sacituzumab govitecan is an antibody-drug conjugate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SG
Description: Sacituzumab govitecan is an antibody-drug conjugate
Study: NCT02814006

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: health educational video
Description: visualization of health educational video

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: health educational video
Description: visualization of health educational video
Study: NCT02582021

Intervention type: PROCEDURE
Intervention: Coronary Angiography
Description: A coronary angiogram is a procedure that uses x-ray imaging to see the heart's blood vessels; it is a part of Heart (cardiac) catheterization procedure. During a coronary angiogram, a type of dye that's visible by an x-ray machine is injected into the blood vessels of the heart. The x-ray machine rapidly takes a series of images (angiograms).~The Coronary Reactivity test (CRT), heart pressure (Millar) evaluation, and Millar stress testing are performed during the coronary angiography.
Study: NCT04486326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crofelemer
Description: Crofelemer
Study: NCT04318977

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-frequency rTMS
Description: repetitive transcranial magnetic stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TBS
Description: theta burst stimulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo transcranial magnetic stimulation
Study: NCT03008291

Intervention type: PROCEDURE
Intervention: CRT-D Implantation
Description: Cardiac resynchronization therapy defibrillator

Intervention type: PROCEDURE
Intervention: CRT-P Implantation
Description: Cardiac resynchronization therapy pacemaker

Intervention type: PROCEDURE
Intervention: Dual Chamber Pacemaker Implantation
Study: NCT04486326

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT01590082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Phase I Starting Dose: 200 mg by mouth twice a day on Day -6 of Cycle 1 (1 week before Day 1 of Cycle 1 starts)~Phase II Starting Dose: Maximum Tolerated Dose (MTD) from Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Phase I and II: 3 mg by vein on Day 1 of each 21 day cycle for 4 cycles.
Study: NCT01349608

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephonic health coaching
Description: Participants will be given a pedometer and activity log to use daily to track their physical activity accomplishments. Weekly, they will participate in a health coaching telephone session to discuss physical activity and set goals. The health coach is knowledgable in COPD care and will utilize a motivational interviewing approach to support the self-efficacy of the participants to be more active.
Study: NCT03751241

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EyeTracker
Description: The EyeTracker is used to determine reading quality of patients with different intraocular lens types (EROV, monofocal, minimonovision)
Study: NCT00837382

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MEDVAMC Nightmare Treatment
Description: Veteran Nightmare Treatment Using Imagery Rescripting

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telepsychiatry Nightmare Treatment
Description: Veteran Nightmare Treatment Using Imagery Rescripting Through Videoconferencing
Study: NCT01590082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Phase I and II: 200 mg/m2 by mouth on Days 1 - 4 of each 21 day cycle for 4 cycles.
Study: NCT04767139

Intervention type: BEHAVIORAL
Intervention: counseling for family planning
Description: all mothers presented to infant immunization units of the selected health centers will be counseled for family planning service and referred to the family planning unit if they decided to use.
Study: NCT04053036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: Participants will be given 1.5mg/kg of MDMA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: Participants will be given 1.5mg/kg of MDMA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: Participants will be given a placebo capsule that will only contain lactose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: Participants will be given a placebo capsule that will only contain lactose.
Study: NCT02262806

Intervention type: DRUG
Group type: OTHER
Intervention: Metreleptin
Description: A leptin analog indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with partial lipodystrophy.
Study: NCT03905707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glepaglutide
Description: Glucagon-Like Peptide-2 (GLP-2) analog

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glepaglutide
Description: Glucagon-Like Peptide-2 (GLP-2) analog
Study: NCT01912677

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Labetalol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methyldopa
Study: NCT02305836

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: For GV16, the needle in length of 25mm will be inserted obliquely and downward towards mandibular direction slowly to a depth of 0.5. And the needle will be pulled out after de qi without being retained. For Shang Yintang, GV20 and GV24, the needle will be inserted with a 30°angle to a depth of about 0.5 cun to the subperiosteum until the patients have a strong sense that the needle is being heavily pressed. For EX-HN5 and KI 4 in both sides, the needle will be outward and obliquely inserted to the same depth of 1 cun and the needle will be manipulated with an even lifting and thrusting method to make the patients feel soreness and distention. The electric stimulator will be put on GV20, GV24 and EX-HN5 in both sides with a spare-dense wave, 10/50 Hz, 0.5-5.0 mA. The current intensity will be increased until the patients can not stand.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: donepezil
Description: cholinesterase inhibitors (ChE-Is)